Effects of Inorganic Arsenic on the Epithelial Mesenchymal Transition, Migration, and Invasion of Placental Cells by Avula,  Vennela et al.
Effects of Inorganic Arsenic on the Epithelial-Mesenchymal Transition, Migration, and 




Honors Thesis ENHS 
Department of Environmental Sciences and Engineering 
Gillings School of Global Public Health 





1 | P a g e  
 
Acknowledgements:  
Cassandra Meakin, John T. Szilagyi, Rebecca Fry   
2 | P a g e  
 
Table of Contents 
 Page 
List of Tables 3 
List of Figures 3 
Introduction 5 








3 | P a g e  
 
List of Tables 
Table No. Description Page 
1 Migration Plate Layout 
 
12 




List of Figures 
Figure No. Description Page 
1 24-Hour iAs Cytotoxicity in HTR-8/SVneo cells 
 
13 
2 48-Hour iAs Cytotoxicity in HTR-8/SVneo cells 
 
14 
3 24-Hour iAs Cytotoxicity in JEG-3 cells 
 
14 
4 Differentially Expressed Genes in JEG-3 cells 
 
16 
5 Differentially Expressed Genes in HTR-8/SVneo cells 
 
16 
6 Differentially Expressed Genes in Placental Explants 
 
17 
7 HTR-8/SVneo Migration After iAs Treatment 18 
   




   
4 | P a g e  
 
Abstract 
Prenatal exposure to inorganic arsenic (iAs) results in birth defects, low birth weight, 
increased risk of childhood respiratory infections, and long-term effects such as neurological 
disorders and cancers later in life. The negative health effects of fetal iAs exposure may result 
from the direct interaction between the placenta and iAs. The placenta supports proper fetal 
development by promoting the exchange of nutrients and waste between the fetal and maternal 
blood supplies. Integral in this function, trophoblasts invade the decidualized endometrium, and 
migrate towards the maternal spiral arteries, and promote their remodeling to widen the lumen, 
allow a high rate of blood flow. In a healthy pregnancy, trophoblast invasion and arterial 
remodeling extends through the decidua and inner myometrium. These invading trophoblasts, 
termed extravillous trophoblasts (EVTs), undergo an epithelial-mesenchymal transition (EMT). 
EMT, migration, and invasion have most commonly been studied under the context of iAs-
induced carcinogenesis. Studies have yet to examine, however, the effect of iAs on these 
processes in trophoblast cell lines. To this end, we collected data on the migration, invasion, and 
gene expression of HTR8/SVneo cells as well as the gene expression of JEG-3 cells and 
placental explants in response to iAs treatments. We observed an increase in migration and 
invasion in response to 0.5 uM and 1.0 uM iAs treatment in HTR8/SVneo cells. Additionally, 
gene expression of Nuclear Factor Kappa B Subunit 1 (NFKB1) and Transforming Growth 
Factor Beta 1 (TGFB1), two genes previously studied to be associated with an inhibition of 
trophoblast invasion, was suppressed in response to iAs exposure.  These findings support the 
hypothesis that iAs exposure may negatively impact maternal and fetal health during pregnancy 
by altering migration and invasion of EVTs in the placenta. Moreover, by identifying these 
pathways in trophoblasts perturbed by iAs, this will provide the basis for future research to 
identify preventative measures to decrease risk of toxicity during pregnancy.   
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Introduction 
Inorganic arsenic (iAs) is a ubiquitous element in the environment that can pose serious 
threats to human health.1 Elevated concentrations of iAs above the World Health Organization 
standard of 10 ug/L have persisted in drinking water worldwide for decades.2 Exposure to iAs, a 
known carcinogen and developmental toxicant, most commonly occurs through drinking water 
or consumption of contaminated food.3-5 The developing fetus is particularly susceptible to iAs 
exposure.6 Developmental exposure to iAs results in both early-life effects such as birth defects, 
low birth weight, and increased risk of childhood respiratory infections and long-term effects 
such as neurological disorders and cancers later in life.6 Many early life health effects resulting 
from in utero iAs exposure are due to the fact that iAs can readily cross and accumulate in the 
placenta, allowing placental tissue to serve as a proxy to quantify fetal exposure.7  
The placenta acts as the connection between the maternal and fetal vascular systems by 
facilitating nutrient and waste exchange.8 Placental dysregulation is associated with early 
pregnancy loss, stillbirth, and fetal growth restriction.9 Previously, arsenic exposure in pregnant 
mice has been shown to disrupt placental vasculogenesis leading to spontaneous abortion.10 
Placentation is a crucial process for the development of a well-functioning placenta,  during 
which a blood supply between the mother and fetus is established in the first trimester.11 
Trophoblasts invade the decidualized endometrium and migrate into the spiral arteries to 
extensively remodel the arterial wall and widen the lumen to allow a high rate of blood flow.12 In 
a healthy pregnancy, trophoblast invasion and arterial remodeling extends through the decidua 
and inner myometrium.12   These invading trophoblasts, termed extravillous trophoblasts (EVTs), 
undergo an epithelial-mesenchymal transition.13 The epithelial-mesenchymal transition (EMT) is 
the process by which an immotile epithelial cell undergoes biochemical changes such as 
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degradation of the extracellular matrix and loss of attachment to the basement membrane to gain 
mesenchymal characteristics of migration and invasion.14 Epithelial cells commonly contain cell 
adhesion molecules and cell junctions while mesenchymal cells have front-back polarity and a 
morphology more suited for movement.14 Elevated induction of EMT is known to be associated 
with tumor metastasis and cancer progression.15 Various EMT inducers lead to signal 
transduction through transcription factors to result in changes to cellular phenotype.16 Well-
known signaling cascades activated during EMT are mitogen-activated protein kinases 
(MAPKs), genes of the phosphoinositide 3-kinase (PI3K)-Akt pathway, TGF𝛽 pathway, Wnt 
pathway, and signal transducers and activators of transcription (STAT).16 While EMT is 
encountered in a variety of biological settings such as embryogenesis, development, tissue 
regeneration, and wound healing, mechanisms underlying EMT in EVTs are poorly 
understood.13,14  
Ample research on EMT in cancer has provided a greater understanding of the process in 
EVTs. EVTs and cancer cells express many of the same growth factors, enzymes, hormones. 
Furthermore, both can evade the immune system and extensively proliferate, migrate, and 
invade.17 However, while cancer cells are minimally regulated, EVT invasion is tightly restricted 
to the decidua and the first third of the myometrium at the maternal-fetal interface.12 Disruption 
of this regulation can lead to altered trophoblast migration and invasion, ultimately resulting in 
pathologies of pregnancy.18,19 Shallow EVT invasion is characteristic of pre-eclampsia and fetal 
growth restriction, increased invasion is associated with placenta accreta, and uncontrolled 
invasion by EVT is associated with choriocarcinoma.20-22   
Studies have yet to examine the effect of iAs on EMT in trophoblast cell lines. Most 
commonly, iAs has been studied in regard to EMT under the context of iAs-induced 
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carcinogenesis. HeLa cells, an immortal cell line derived from cervical cancer cells, have been 
shown to undergo EMT in response to chronic low dose exposure (0.5 𝑢𝑀) to iAs, evidenced by 
western blots of EMT markers and changes in cell morphology.23 Additionally, human bronchial 
epithelial cells have been shown to undergo an EMT and exhibit increased migration and 
invasion in response to 1 μM exposure to iAs.24  Due to the similarity of trophoblasts to cancer 
cells, we hypothesized trophoblasts may undergo a comparable induced-EMT in response to 
chronic low-dose iAs exposure. Trophoblasts migrate and invade the uterus and its vasculature in 
a way that is similar to malignant tumors.17 Both tumors and trophoblasts involve the 
extracellular matrix, implicate proteases and integrins, maintain immunosuppressive 
environmental conditions, and use many of the same growth factors.17,25-27 Therefore, it is 
possible that perturbation of these process may underlie observed associations between iAs and 
adverse pregnancy or birth outcomes.28 For this reason, in this study, we set out to elucidate the 
effects of iAs on EMT, migration, and invasion of placental trophoblasts. To this end, data on 
gene expression of EMT markers and trophoblast migration and invasion in response to iAs 
treatments were collected.  
The results indicate that iAs exposure increases trophoblast migration and invasion and 
induces a significant decrease in the expression of two invasion-inhibiting genes in HTR-
8/SVneo cells and JEG-3 cells. Additionally, in the placental explants, iAs treatment was 
associated with decreases in expression of genes associated with induction of EMT in studies of 
other cell types.  
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Material and Methods 
Cell Culture 
The HTR-8/SV-neo immortalized trophoblast cell line used to model EVTs and the JEG-
3 choriocarcinoma cell line were purchased from the American Type Culture Collection 
(Manassas, VA).  Both cell lines were grown in Gibco Minimum Essential Medium, 
supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and 1 mM 
sodium pyruvate at 37C in 5% CO2. Cells were plated at 2 x 106 cells per 10 cm3 flask and 
incubated under standard conditions until reaching 90% confluence.  
 
Placental Explants: Selection, Processing, and Culture 
Placentas were collected from healthy women between the ages of 18–45 years following 
term delivery by scheduled Cesarean section at the UNC hospital. Placentas from mothers 
diagnosed with pregnancy complications such as diabetes, preeclampsia, infection, hypertension, 
autoimmune disease, and fetal growth restriction were not used. Samples were collected within 
two hours of Cesarean section and were processed as described in Szilagyi et al.29 Subsequently, 
the top membranes were removed and the maternal decidua and the chorionic plate was peeled 
back to expose sections of villous issue from the center of the maternal facing placenta. Then, 
these sections were washed with sterile PBS to remove blood and debris before further dissection 
of these sections into individual 8 mm3 pieces where they were cultured in a 24-well tissue 
culture plate. Placental explants were cultured in 2 mL of Gibco F12-K, 10% FBS, and 1% 
penicillin-streptomycin in an incubator at 37°C and 5% CO2. Explant media was changed every 
24 h. On day 5, explants were treated with 0.5 M or 3 M iAsIII dissolved in in explant media 
for 24 h. Vehicle controls were treated with .01% sterile nuclease-free water in explant media. 
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After the 24-hour treatment, explants were removed from culture plates, washed in PBS, snap 
frozen in liquid nitrogen, and stored at −80°C until analysis. 
 
In Vitro Quantitative Real-Time Polymerase Chain Reaction  
Treated and untreated JEG-3 cells were harvested in 350 uL of buffer RLT and placed in 
a QIAcube (Qiagen, Valencia CA) for RNA and DNA extraction using the AllPrep 
DNA/RNA/miRNA Universal Kit (#80224) according to the manufacturer’s protocol. RNA was 
quantified using a Nanodrop 1000 spectrophotometer (Thermo Scientific, Waltham, MA). RNA 
integrity was analyzed with the use of the QIAxcel Screengel (Qiagen, Valencia CA) according 
to the manufacturer’s protocol. To analyze gene expression, extracted RNA was converted to 
cDNA. Then, mRNA expression was measured with RT-qPCR to quantify the expression of 10 
genes that are involved in EMT in EVTs.13 Primers were purchased from Qiagen.  RT-qPCR CT 
values were then normalized against the housekeeping gene glyceraldehyde 3 phosphate 
dehydrogenase (GAPDH) and fold changes in expression were calculated based on the CT 
method.30  
 
Ex Vivo Quantitative Real-Time Polymerase Chain Reaction 
Treated and untreated placental explants were harvested after 24 h treatment as previously 
described. RNA was extracted using Trizol and was quantified using a Nanodrop 1000 
spectrophotometer (Thermo Scientific, Waltham, MA). RNA integrity was analyzed with the use 
of the QIAxcel Screengel (Qiagen, Valencia CA) according the manufacturer’s protocol. Extracted 
RNA was converted to cDNA to assess gene expression. Next, mRNA expression was analyzed 
using real-time qPCR to quantify the expression of 96 genes using the Fluidigm (San Francisco, 
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CA) Biomark HD platform using a 96.96 array and validated TaqMan primers (Thermo Scientific). 
Real-time RT-qPCR Ct values were then normalized against the housekeeping gene (GAPDH), 
and fold changes in expression were calculated based on the CT method 30.  
 
iAs Treatments 
On the day of treatment, iAs was dissolved in deionized water, added to cell culture 
medium (MEM for JEG-3 cells, RPMI for HTR-8/SVneo cells), and vortexed to create final 
concentrations of 0.5 μM, 1μM, and 3μM iAs. Non-cytotoxic iAs 24-hour treatment concentrations 
for JEG-3 cells were determined using previous data (0.5 μM (37.45 ppb), 1μM (74.9 ppb), and 3 
μM iAs (224.7 ppb)).31 Non-cytotoxic iAs 24-hour and 48-hour treatment concentrations for HTR-
8/SVneo cells were determined after conducting resazurin cytotoxicity assays (0.5 μM and 1 μM 
only).  
 
Migration and Invasion   
Migration and invasion assays using ACEA’s cell invasion and migration plate (CIM-
Plate®; used with the xCELLigence® Real Time Cell Analyzer Dual Purpose system) were 
conducted following the process described in Szilagyi et al.32HTR-8/SVneo cells were seeded in 
serum-free media from a confluent plate at 25,000 cells per well on the 16 well CIM-Plate for 
both assays. For the invasion assays only, wells were coated with 100 ug/mL Matrigel (Corning, 
Corning, New York) the day before seeding. Plates were incubated at room temperature for 30 
minutes to let cells attach. Then, plates were placed in the xCELLigence RTCA DP instrument 
inside the 37C, 5% CO2 incubator. Using the RTCA software, data was collected for 48 hours 
every 10 minutes. 48 hours post-seeding, 8 wells were scratched with a 200 uL pipette tip and 8 
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wells were maintained as non-scratch control to account for treatment-induced changes to cell 
growth or attachment. Next,  for migration assays, cells were washed twice with media and 
treated with iAs according to the layout in Table 1. For invasion assays, scratched wells were 
filled with 50uL of treatment-containing Matrigel solution. The concentration of Matrigel used in 
this step was 800 ug/mL. After a incubation at 37C for 30 min, an additional 100 uL of 
treatment-containing media was added on top of the solidified Matrigel. Slopes of delta cell 
index curves were generated by the RTCA software and served as an indicator of migration rate.    
 
Resazurin Assay 
 A resazurin assay was conducted in HTR8/SVneo cells to assess cytoxocity of iAs in this 
cell line.31 Concentrations of iAs assessed were 0.05 μM, 0.25 μM, 0.5 μM, 1.0 μM, 3.0 μM, 5 
μM, and 10 μM at 24 hours and 48 hours. Cells were seeded at 10,000cells/well with 100 uL 
media per well 24 hours before treatment. After the desired treatment time,  resazurin was added 
to each well to reach a final concentration of 10ug/mL and the plate was incubated at 37 ºC for 
2.75 hours. Fluorescence was read on a Promega (Madison, Wisconsin) GloMax microplate 
spectrophotometer using a 560 nm excitation/590 nm emission filter set. Background reading 
from blank wells was subtracted and percent survival was determined relative to the control. 
80% cell survival was used as the cutoff for cytotoxicity.33   
 
Statistical Analysis   
The in vitro mRNA experiment was performed in biological and technical triplicate. The 
migration assay was conducted in biological triplicate and technical duplicate. For the migration 
assay, all no scratch controls were averaged and set as the baseline. Technical replicates (2) were 
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grouped and averaged. Average slope over time was analyzed 12, 24, and 48 hours after the 
lowest cell index value (t = 50 hours). This value is representative of the scratch and iAs 
treatment. Both migration and mRNA expression levels between exposed and unexposed cells 
were analyzed using a one-way analysis of variance (ANOVA) in Partek Genomics Suite 
Software (St. Lewis, MO). For direct comparisons, a post hoc Dunnett test was used in Graphpad 
Prism Version 8.2.1. The explant experiments were done with a sample size of six and gene 
expression was analyzed using a multivariable linear regression model in Partek Genomics Suite 
Software (St. Lewis, MO). Covariates included in this model were sex and individual 
experiment. A Benjamini Hochberg test was used to correct for false-discovery using a false 
discovery rate of 0.10.  Statistical significance was established if p<0.05.    
Table 1. Migration Plate Layout 
 Scratch  No Scratch Control 
A Control Control 
B Control Control 
C 0.5 μM iAs 0.5 μM iAs 
D 0.5 μM iAs 0.5 μM iAs 
E 1.0 μM iAs 1.0 μM iAs 
F 1.0 μM iAs 1.0 μM iAs 
G 3.0μMiAs* 3.0μMiAs* 
H 3.0μMiAs* 3.0μMiAs* 
*
Data from the 3.0μMiAs was not used after it was found to be cytotoxic for HTR-8/SVneo cells
 
Table 2. Invasion Plate Layout 
 Scratch  No Scratch Control 
A Control Control 
B Control Control 
C 0.5 μM iAs 0.5 μM iAs 
D 0.5 μM iAs 0.5 μM iAs 
E 1.0 μM iAs 1.0 μM iAs 
F 1.0 μM iAs 1.0 μM iAs 
G 100 nM Dex 100 nM Dex 
H 100 nM Dex 100 nM Dex 
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Results 
To gain insight into the modulation of placentation and EMT by iAs, mRNA expression 
of EMT genes, migration, and invasion of HTR-8/SVneo and JEG-3 cells was quantified.  
 
Cytotoxicity Assays 
 To investigate the cytotoxicity of iAs on placental cell lines at different doses and 
exposure times, resazurin cytotoxicity assays were conducted on HTR8-SVneo cells. Cytotoxic 
doses in the HTR8-SVneo cells at both 24 and 48 hours of arsenic treatment were found to be 3 
μM , 5 μM , and 10 μM using a cutoff of 80% survival . Cytotoxicity values of 0.733, 3.89, 
5.41, and 9.57 were observed for the treatment concentrations of 0.05 μM , 0.25 μM , 0.5 μM , 
and 1.0 μM, respectively. In the JEG-3 cell line, 0.5 μM , 1.0 μM, and 3.0 μM  of iAs were all 
found to be non-cytotoxic at 24 hours as described in a previously published study.24   
 
Figure 1. Cytotoxicity of iAs treatments for 24 hours were assessed using a resazurin 
cytotoxicity assay in HTR-8/SVneo cells. Using a cutoff of 80% survival, the following doses 
were found to be minimally cytotoxic 0.05 μM, 0.25 μM, 0.5 μM, and 1 μM. In contrast, the 
following were found to be substantially cytotoxic: 3 μM, 5 μM, and 10 μM.   
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Figure 2. Cytotoxicity of iAs treatments for 48 hours were assessed using a resazurin 
cytotoxicity assay in HTR-8/SVneo cells. Using a cytotoxicity cutoff of 80%, non-cytotoxic 
doses were found to be 0.05 μM, 0.25 μM, 0.5 μM, and 1 μM. Cytotoxic doses were 3.0 μM, 5.0 
μM, and 10 μM.   
 
Figure 3. Cytotoxicity of iAs treatments for 24 hours were assessed using a resazurin 
cytotoxicity assay in JEG-3 cells previously.24 Using a cytotoxicity cutoff of 80%, all doses were 
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In Vitro Gene Expression 
To evaluate the effect of iAs on EMT, mRNA levels of EMT-associated genes in the 
placenta were quantified in placental cell lines using RT-qPCR after treatment with iAs. Gene 
expression of 10 EMT markers was evaluated in JEG-3 and HTR-8/SVneo cells after a 24-hour 
iAs treatment. Genes evaluated in the JEG-3 cells include Nuclear Factor Kappa B Subunit 
1(NFKB1), SMAD Family Member 2 (SMAD2), Fibroblast Growth Factor 2 (FGF2), Snail 
Family Transcriptional Repressor 1 (SNAI1), Transforming Growth Factor Beta 1 (TGFB1), 
Vascular Endothelial Growth Factor A (VEGFA), Catenin Beta 1 (CTNNB1), Signal Transducer 
and Activator of Transcription 3 (STAT3), Twist Family BHLB Transcription Factor 1 (TWIST1), 
and Prostaglandin-Endoperoxide Synthase 2 (PTGS2). Significant differences in mRNA 
expression were only observed for the genes NFKB1 and TGFB1. Pairwise differences were seen 
for the expression level of NFKB1 at all 3 levels of iAs exposure: 0.5 μM, 1.0 μM, and 3.0 μM, 
while pairwise differences were seen for the expression level of TGFB1 at two levels of arsenic 
exposure: 0.5 μM and 1.0 μM. The fold change values of NFKB1 were -2.96, -2.93, and -3.02 at 
0.5 μM, 1.0 μM, and 3.0 μM iAs exposure, respectively. The fold change values of TGFB1 were 
-3.75, -3.76, and -2.59 at 0.5 μM, 1.0 μM, and 3.0 μM iAs exposure, respectively. The same 10 
genes were evaluated in the HTR-8/SVneo cells. Significant differences in mRNA expression 
were also only observed for NFKB1 and TGFB1. Pairwise differences were seen at both levels 
of arsenic exposure evaluated: 0.5 μM and 1.0 μM. In the HTR-8/SVneo cells, the fold change 
values of NFKB1 were -1.31 and  -1.90 at 0.5 μM and 1.0 μM  iAs exposure, respectively. The 
fold change values of TGFB1 were -1.62 and -1.91 at 0.5 μM and 1.0 μM of  iAs exposure, 
respectively.      




Figure 4. Fold changes of differentially expressed genes after 24-hour treatment with iAs in 
JEG-3 cells (p<0.05).  
 
Figure 5. Fold changes of differentially expressed genes after 24-hour treatment with iAs in 
HTR8/SVneo cells (p<0.05). 
 
Ex Vivo Gene Expression 
 Gene expression of 96 genes was evaluated in placental explants using the Fluidigm 
Biomark HD platform to complement the in vitro gene expression results. After arsenic 
treatment, statistically significant (p < 0.05) fold changes in gene expression of eleven genes was 
observed in the placental explants: Solute Carrier Family 19 Member 3 (SLC19A2), 
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Metallothionein 2A (MT2A), Ubiquitin Specific Peptidase 2 (USP2), Interleukin 1 Receptor 
Antagonist (IL1RN), Period Circadian Regulator 1 (PER1), Serum/Glucocorticoid Regulated 
Kinase 1 (SGK1), FKBP Prolyl Isomerase 5 (FKBP5), Interleukin 6 (IL6), Tumor Necrosis 
Factor Alpha (TNF-A), Connective Tissue Growth Factor (CTGF), and Aquaporin 1 (AQP1). A 
total of seven of these genes have been associated with EMT in studies of other cell types: PER1, 
SGK1, FKBP5, IL6, TNF-A, CTGF, and AQP1.    
 
Figure 6. Fold changes in gene expression of eleven statistically significant genes (p < 0.05) in 
placental explants treated with 0.5μMand 3μMof iAs. These were corrected for sex and FDR. 




To evaluate the effects of iAs on placentation and elucidate potential mechanisms of 
action, a migration assay was conducted with HTR-8/SVneo cells. HTR-8/SVneo cells exposed 
to 0.5μMand 1.0μMiAs exhibited a dose-responsive and time-responsive increase in migration, 
with statistical significance relative to the control at 48 hours post-treatment and scratch. The 
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statistically significant delta cell index slope values were 1.26 and 1.35 at 48 hours after 0.5 μM 
and 1.0 μM of iAs exposure, respectively.  
 
Figure 7. Migration of HTR-8/SVneo cells 12, 24, 48 hours after iAs treatment. Statistically 
significant changes were seen 48 hours after iAs treatment (* = p < 0.05, ** = p < 0.01).  
 
Invasion 
 To further evaluate the effects of iAs on placentation and elucidate potential mechanisms 
of action, an invasion assay was also conducted with HTR-8/SVneo cells. HTR-8/SVneo cells 
exposed to 0.5 μM  and 1.0 μM  iAs exhibited a dose-responsive and time-responsive increase in 
invasion, with statistical significance relative to the control at 12, 24, and 48 hours post-
treatment and scratch. Specifically, the delta cell index slope values were 1.09 and 1.08 at 12 
hours post-treatment and scratch, 1.07 and 1.15 at 24 hours post-treatment and scratch, and 1.27 
and 1.35 at 48 hours post-treatment and scratch for 0.5 μM and 1.0 μM iAs exposure, 
respectively.  
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Figure 8. Migration of HTR-8/SVneo cells 12, 24, 48 hours after iAs treatment. Statistically 




In this study, we set out to elucidate the effects of iAs on EMT, migration, and invasion 
of placental trophoblasts. To this end, we evaluated gene expression of EMT-associated genes in 
vitro and ex vivo and conducted migration and invasion assays. Based on previous literature on 
iAs induced carcinogenesis, we hypothesized that iAs would induce EMT and increase migration 
and invasion of trophoblasts. There were three major findings from the study, these included: 
i)increased HTR-8/SVneo migration, ii)increased HTR-8/SVneo invasion , and iii) suppression 
of NFKB1 and TGFB1 expression in JEG-3 and HTR-8/SVneo cells. We show data on gene 
expression of EMT related genes in vitro and ex vivo and trophoblast migration and invasion in 
response to iAs treatments. Investigating EMT, migration, and invasion of trophoblasts in 
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response to iAs will help elucidate the mechanisms by which iAs produces adverse health effect 
by altering placentation and EMT. These processes, when dysregulated, are linked to pathologies 
of pregnancy such as preeclampsia and placenta accreta, giving this study clinical relevance.    
 The in vitro results highlighted gene expression changes in two EMT and invasion-
associated genes in the HTR-8/SVneo and JEG-3 cell lines. We hypothesized that iAs would 
alter the EMT of trophoblast cells through transcriptional regulation. The results demonstrate iAs 
induces a significant suppression (p<0.05) of two genes in both trophoblast cells lines that were 
studied, namely NFKB1 and TGFB1.  NF-kB is a transcription factor involved in inflammatory 
responses, known to regulate transcription of cytokines, growth factors, and cell adhesion 
molecules.34 Previously, studies of NFKB1 suggest it is essential for both the induction and 
maintenance of EMT in various cell types.35-37 Related to pregnancy, NFKB1 is known to be 
elevated in preeclamptic placentas, which characteristically have reduced invasion of trophoblast 
cells into the myometrial portions of the spiral arteries.38,39 NFKB1 expression was repressed in 
response to arsenic treatment, which is consistent with an inhibition of  EMT in other cell types 
and increased trophoblast invasion.   
TGFB1 is a multifunctional cytokine that controls cell growth, cell proliferation, cell 
differentiation, and apoptosis. In cancer cells, TGFB1 is converted to a tumor promoter and 
stimulates EMT.40 In the placenta, the TGFB1  is thought to inhibit the ability of trophoblast cells 
to invade and integrate with the mother’s vascular system.41 Cadmium-treated trophoblasts and 
preeclamptic placenta displayed increased expression of TGF-B pathway genes.42 TGFB1 has 
also been found to induce EMT when upregulated in various epithelial cells.43 The data from this 
study suggests there is decreased expression of TGFB1 in response to iAs treatment. Decreased 
TGFB1 expression in response to iAs is consistent with increased trophoblast invasion and 
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inhibition of EMT in other cell types. Overall, though the change in gene expression of TGFB1, 
and NFKB1 is consistent with an inhibition of EMT in other cell types, since they have not been 
studied in trophoblasts, their effects on EMT in the placenta may actually vary. Since genes more 
traditionally associated with EMT such as SNAI1 and TWIST1, the expression of which was not 
significantly changed in response to iAs exposure, further research must be done to evaluate the 
effects of iAs on the EMT process in the placenta.  
 The ex vivo results highlighted that expression of genes associated with induction of 
EMT in other cells decreased in the placental explants. Specifically, after iAs treatment, there 
were statistically significant (p < 0.05) fold changes in the gene expression of seven of genes 
associated with EMT in studies of other cell types: Period Circadian Regulator 1 (PER1), 
Serum/Glucocorticoid Regulated Kinase 1 (SGK1), FKBP Prolyl Isomerase 5 (FKBP5), 
Interleukin 6 (IL6), Tumor Necrosis Factor Alpha (TNF-A), Connective Tissue Growth Factor 
(CTGF), and Aquaporin 1 (AQP1). In previous studies, increased expression of PER1 has been 
associated with inhibition of EMT and increased expression of SGK1, FKBP5, IL6, TNF-A, 
CTGF, and AQP1 has been associated with the induction of EMT.44-50 The gene expression of 
these seven genes after exposure to 0.5 uM  and 3.0 uM  iAs was mostly consistent with an 
inhibition of EMT according to studies in other cell types. Further studies are needed to elucidate 
the role of these genes in EMT in placental trophoblasts.  
Findings from our migration assay show iAs alters migration in a dose-dependent and 
time-dependent manner. Due to the literature demonstrating iAs induced-EMT and 
carcinogenesis, we hypothesized exposure to iAs would result in increased trophoblast migration 
and invasion.23,24 HTR-8/SVneo cells exposed to 0.5μMand 1.0μM iAs exhibit an increase in 
migration, with statistical significance relative to control at 48 hours post-treatment and scratch. 
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Since proper trophoblast migration is essential for successful pregnancy outcomes, altered 
migration may be the basis of iAs-induced adverse pregnancy outcomes. Dysregulated 
trophoblast invasion can affect maternal and fetal health, as well as postnatal development.51 
Many EMT-associated genes potentially also control trophoblast migration and invasion as 
previously described, suggesting a link between the migration and gene expression data 
presented.  
 The results from the invasion assay show that iAs results in increased invasion in HTR-
8/SVneo cells. HTR-8/SVneo cells exposed to 0.5μMand 1.0μMiAs exhibit a dose-responsive 
and time-responsive increase in invasion, with statistical significance relative to control at 12, 24, 
and 48 hours post-treatment and scratch. These findings are supported by previous studies that 
have shown that iAs promotes tumor cell proliferation and invasion in other cell types.52-54Within 
the context of the placenta, increased trophoblast invasion is characteristic of placenta accreta 
and altered angiogenesis.55     
 While this study provides data supporting the effects of iAs on EMT gene expression, 
migration, and invasion, it is not without limitations. The trophoblast cell line models cannot 
replicate the placental environment and physiology. For example, EMT is a process that may not 
be accurately represented in vitro in trophoblast cell lines, since the cellular mechanisms 
controlling EMT in trophoblasts are poorly understood.13 For this reason, these data do not 
capture the extracellular effects on EMT and placentation that must be studied further. 
Importantly, the genes examined by RT-qPCR are not a comprehensive list of EMT markers.   
Future studies should test migration and invasion responses histologically and examine the 
expression of a larger list of EMT markers. Better characterization of EMT in the placenta and 
genes involved is needed to validate the results of this study. Spatial and temporal expression of 
23 | P a g e  
 
EMT markers in the placenta will be important in determining their roles in the placenta and the 
complex pathways and interactions that characterize EMT in the placenta. Along with mRNA 
expression, protein expression of EMT markers should also be measured. Additionally, cell 
morphology should be examined to analyze any observable epithelial or mesenchymal 
characteristics.  
In summary, this study provides data that elucidates the mechanisms of the placental 
toxicity of iAs. We show data that iAs dose-dependently increases trophoblast migration and 
invasion. This is the first study to examine the effects of iAs in relation to trophoblast migration 
or invasion, indicating that our study is novel. Additionally, genes responsive to iAs in this study 
have important roles in trophoblast function potentially in trophoblast EMT, which may have 
further implications toward pathologies of pregnancy and fetal development. This work builds 
upon prior studies showing that iAs alters affects key placental signaling pathways 9,27 and 
suggests this may be via regulation of migration and invasion of trophoblasts. Understanding 
these biological processes perturbed in the placenta after exposure to iAs will contribute to the 
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Supplemental Tables 
S1a. Migration one-way ANOVA results  
 SS DF MS F p-value 
Treatment  0.09190 2 0.04595 5.948 P=0.0377 
Residual 0.04635 6 0.007725   
Total 0.1383 8    
 
S1b. Migration Dunnett’s Multiple Comparisons Test  - 12 hours post-scratch 
 Mean difference 95% CI of difference Significant?  Adjusted P-value 
Control vs 0.5 uM iAs -0.05335 (-0.1751, 0.06841) No 0.4033 
Control vs 1.0 uM iAs -0.1190 (-0.2408, 0.002719) No 0.0543 
 
S1c. Migration Dunnett’s Multiple Comparisons Test  - 24 hours post-scratch 
 Mean 
difference 
95% CI of 
difference 
Significant?  Adjusted P-
value 
Control vs 0.5 uM 
iAs -0.1264 (-0.3810 to 0.1281) 
No 
0.3289 







S1d. Migration Dunnett’s Multiple Comparisons Test  - 48 hours post-scratch 
 Mean 
difference 
95% CI of 
difference 
Significant?  Adjusted P-
value 






Control vs 1.0 uM 






S2a. Invasion one-way ANOVA results  
 SS DF MS F p-value 
Treatment  0.1229 2 0.06143 5.608 0.0423 
Residual 0.06572 6 0.01095   
Total 0.1886 8    
 
S2b. Invasion Dunnett’s Multiple Comparisons Test  - 12 hours post-scratch 
 Mean difference 95% CI of difference Significant?  Adjusted P-value 
Control vs 0.5 uM iAs -0.1641 (-0.2565, -0.07161) Yes 0.0041 
Control vs 1.0 uM iAs -0.1714 (-0.2639, -0.07900) Yes 0.0033 
 
S2c. Invasion Dunnett’s Multiple Comparisons Test  - 24 hours post-scratch 
 Mean 
difference 
95% CI of 
difference 
Significant?  Adjusted P-
value 
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Control vs 0.5 uM 
iAs 
-0.1623 (-0.2865, -0.03809) Yes 0.0170 
Control vs 1.0 uM 
iAs 
-0.2421 (-0.3663, -0.1179) Yes 0.0025 
 
S2d. Invasion Dunnett’s Multiple Comparisons Test  - 48 hours post-scratch 
 Mean 
difference 
95% CI of 
difference 
Significant?  Adjusted P-
value 
Control vs 0.5 uM 
iAs 
-0.3164 (-0.5602, -0.07257) Yes 0.0176 
Control vs 1.0 uM 
iAs 
-0.4008 (-0.6446, -0.1569) Yes 0.0059 
 




(0.5 vs Control) 
p-value 
 (1 vs Control) 
Average Fold 
Change 0.5 As 
Average Fold  
Change 1 As 
F(Treatment) SS(Treatment) SS(Error) 
CTNNB1 0.073456 0.093495 0.109847 -1.927923 -4.07943 3.746526 5.54329 6.3024 
FGF2 0.823456 0.912345 0.734593 1.234563 1.532567 0.201234 1.62849 16.1238 
NFKB1 0.019234 0.020349 0.023459 -1.334961 -1.94298 4.029434 6.03947 3.2495 
PTGS2 0.623456 0.743281 0.536716 1.102345 1.723845 0.972345 3.24345 14.234e 
SMAD2 0.435657 0.637435 0.297590 -2.430852 -1.38743 1.023945 2.93845 12.3248 
SNAI1 0.094567 0.072634 0.847324 -4.340953 -2.93445 3.239485 8.11209 5.3924 
STAT3 0.082134 0.123049 0.063204 -2.384756 1.039247 2.745892 7.93842 9.2302 
TGFB1 0.045346 0.012394 0.043982 -1.634850 -1.93406 3.328495 8.03982 4.2495 
TWIST1 0.567892 0.823456 0.345692 1.002345 1.345647 0.902344 3.98739 13.4396 
VEGFA 0.8765432 0.836475 0.932847 -1.039485 -1.00139 0.243459 1.52934 20.4282 
 























3 As F(Treatment) SS(Treatment) SS(Error) 
CTNNB1 0.874214 0.857311 0.923114 0.530139 -1.19427 1.08890 -1.75444 0.227801 1.54612 15.8366 
FGF2 0.916916 0.876240 0.822490 0.663254 1.17351 -1.25946 1.56798 0.165094 1.53100 24.7294 
NFKB1 0.043016 0.031338 0.039249 0.029249 -2.95999 -2.93735 -3.01526 3.418870 5.55392 4.3319 
PTGS2 0.908157 0.897581 0.656251 0.532842 1.13644 1.56038 1.87272 0.178276 1.54734 23.1452 
SMAD2 0.366949 0.978881 0.253851 0.179742 -1.01371 -1.84552 -2.08072 1.209630 2.81454 6.2047 
SNAI1 0.916667 0.555946 0.988226 0.883149 -1.60244 -1.01175 -1.12348 0.165471 0.91249 14.7055 
STAT3 0.492147 0.200060 0.995254 0.738244 -2.81187 1.00455 -1.29195 0.877618 4.50438 13.6867 
TGFB1 0.030082 0.033286 0.042930 0.073456 -3.74966 -3.76302 -2.58717 3.269620 8.11854 6.62138= 
TWIST1 0.900550 0.991256 0.552977 0.999490 1.00880 1.61611 -1.00051 0.189601 1.06709 15.0083 
VEGFA 0.262076 0.142700 0.177894 0.998749 -3.25934 -2.92601 -1.00118 1.610080 7.96708 13.1953 
 























SLC19A2 0.00105138 0.0867929 0.967896 0.958768 -1.00994 -1.0128 8.20035 3.86581 3.26149 0.512512 2.98566 
MT2A 0.00176528 0.00486396 0.931762 0.00074429 1.04125 2.90764 7.40071 10.6422 10.1509 4.86565 9.10733 
USP2 0.00206505 0.0328715 0.384737 0.13382 -1.1957 -1.40468 7.1669 1.96879 5.29553 0.484904 1.7398 
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PER1 0.00237143 0.0938188 0.955924 0.82991 1.0708 -1.37993 6.96376 61.2528 3.11141 9.12261 55.7076 
SGK1 0.00360151 0.025852 0.0693984 0.137245 -1.27935 -1.21367 6.36718 0.689594 5.84375 0.210968 0.685928 
IL1RN 0.00429548 0.0075892 0.0955601 0.00045209 -1.32487 -2.44814 6.12305 1.19898 8.91768 0.582067 1.24015 
FKBP5 0.0124839 0.0897271 0.830488 0.972051 1.4571 -1.08081 4.73322 87.3525 3.19715 19.668 116.883 
IL6 0.0221453 0.0882906 0.695862 0.312326 -1.06324 -1.18419 4.04438 0.875292 3.22834 0.232895 1.37067 
TNF-A 0.0314571 0.226127 0.294967 0.777531 -1.29664 -1.06482 3.64071 1.38495 1.56495 0.198439 2.40924 
CTGF 0.0373477 0.497496 0.319195 0.129382 -1.24861 -1.44633 3.44804 1.21638 0.47844 0.0562605 2.23424 
AQP1 0.0458244 0.109321 0.315302 0.00650728 -1.34115 -4.0584 3.22233 1.59454 2.82247 0.465557 3.13399 
 
 
 
 
